^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersBIOMARKER:
EGFR S768I
i
Other names: EGFR, ERBB, ERBB1, Epidermal growth factor receptor
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
Related tests:
3d
REZILIENT2: A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation. (clinicaltrials.gov)
P2, N=324, Recruiting, Taiho Oncology, Inc. | N=224 --> 324 | Trial completion date: Aug 2026 --> Dec 2028 | Trial primary completion date: Feb 2026 --> Aug 2028
Enrollment change • Trial completion date • Trial primary completion date
|
EGFR (Epidermal growth factor receptor)
|
EGFR L858R • EGFR exon 19 deletion • EGFR L861Q • EGFR G719X • EGFR S768I
|
zipalertinib (CLN-081)
3d
Case Report: A patient harboring rare EGFR S768I/V769L compound mutation benefited from afatinib and osimertinib. (PubMed, Front Pharmacol)
After multi-disciplinary treatment, the patient received concurrent chemoradiotherapy with pemetrexed and cisplatin, and achieved partial response. This patient did not receive durvalumab immunoconsolidation therapy for economic reasons...Patients with EGFR S768I/V769L compound mutated NSCLC may benefit from afatinib and osimertinib. Drugs with strong brain penetration capabilities are still needed for patients with S768I/V769L compound mutation to further improve survival outcomes.
Journal • PD(L)-1 Biomarker
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR exon 20 insertion • EGFR S768I
|
cisplatin • Tagrisso (osimertinib) • Gilotrif (afatinib) • Imfinzi (durvalumab) • pemetrexed • simmitinib (SYHA1817)
10d
Favorable response to third-generation TKI furmonertinib in a patient with early-stage non-small cell lung cancer harboring rare compound EGFR mutations: Exon 18 G719C and Exon 20 S768I - A Case Report. (PubMed, Front Oncol)
Here, we describe a case of early-stage non-small cell lung cancer (NSCLC) harboring a G719C+S768I compound mutation that achieved complete remission following treatment with furmonertinib. These findings suggest that furmonertinib may represent a promising therapeutic option to improve cure rates in this subset of patients.
Journal
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR S768I
|
Ivesa (firmonertinib)
12d
Adjuvant icotinib and osimertinib in the treatment of EGFR-mutated resectable non-small cell lung cancer: A real-world multicenter cohort study in China (ChiCTR2500112843)
P=N/A, N=200, Not yet recruiting, Beijing Chest Hospital Capital Medical University; Beijing Chest Hospital Capital Medical University
New trial
|
EGFR (Epidermal growth factor receptor) • TP53 (Tumor protein P53)
|
TP53 mutation • EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q • EGFR G719X • EGFR S768I
|
Tagrisso (osimertinib) • Conmana (icotinib) • simmitinib (SYHA1817)
12d
A prospective clinical study on the efficacy and safety of Limerinib Tablets in the treatment of local advanced or recurrent metastasis of EGFR mutation with meningeal metastasis and non-scaly NSCLC (ChiCTR2500111717)
P=N/A, N=60, Not yet recruiting, The First Affiliated Hospital of Zhengzhou University; The First Affiliated Hospital of Zhengzhou University
New trial
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q • EGFR G719X • EGFR S768I
12d
Limertinib Plus Platinum-Based Chemotherapy in Patients with Advanced EGFR-Mutated Non-Squamous NSCLC after Progression on First-Line EGFR-TKI Therapy : A Single-Arm, Multicenter Study (ChiCTR2500114831)
P2, N=61, Not yet recruiting, Qilu Hospital of Shandong University; Qilu Hospital of Shandong University
New P2 trial
|
EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I
|
cisplatin • carboplatin • pemetrexed • limertinib (ASK120067)
12d
A prospective single-arm phase II clinical trial on the sacituzumab tirumotecan treatment of targeted therapy pre-treated, advanced or metastatic non-small cell lung cancer patients with EGFR uncommon mutations (ChiCTR2500114453)
P2, N=30, Not yet recruiting, Cancer Hospital Chinese Academy of Medical Sciences; Cancer Hospital Chinese Academy of Medical Sciences
New P2 trial
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR L861Q • EGFR G719X • EGFR S768I
|
Jiataile (sacituzumab tirumotecan)
12d
Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of BL-B01D1 for Injection in Patients with Locally Advanced or Metastatic Solid Tumors (ChiCTR2500113663)
P1, N=500, Not yet recruiting, Sun Yat-sen University Cancer Center; Sichuan Baili Pharmaceutical Co., Ltd.
New P1 trial
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)
|
BRAF V600E • KRAS mutation • EGFR mutation • KRAS G12C • BRAF V600 • RET fusion • MET exon 14 mutation • ALK fusion • EGFR L861Q • RET mutation • ROS1 fusion • EGFR G719X • MET mutation • EGFR S768I • KRAS G12 • NTRK fusion
|
izalontamab brengitecan (BL-B01D1)
12d
A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of BG-60366 in Patients With EGFR-Mutant Non-Small Cell Lung Cancer (ChiCTR2500113951)
P1, N=258, Not yet recruiting, Guangdong Provincial People's Hospital(Guangdong Academy of Medical Sciences); Guangdong Provincial People's Hospital(Guangdong Academy of Medical Sci
New P1 trial
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q • EGFR G719X • EGFR S768I
12d
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Anti-tumor Efficacy of HJ-004-02 Tablets in Patients with Advanced Non-squamous Non-small Cell Lung Cancer with Epidermal Growth Factor Receptor (EGFR) Mutations (ChiCTR2500112428)
P1, N=36, Not yet recruiting, Shanghai East Hospital; Jing Medicine Technology (Shanghai) Co., Ltd.
New P1 trial
|
EGFR mutation • EGFR L858R • EGFR T790M • EGFR exon 20 insertion • EGFR expression • EGFR L861Q • EGFR S768I • EGFR positive
15d
Zipalertinib-A Novel Treatment Opportunity for Non-Small Cell Lung Cancers with Exon 20 Insertions and Uncommon EGFR Mutations. (PubMed, Cancers (Basel))
The role and the integration of therapies targeting exon20ins or uncommon mutations into the first- and second-line treatment armamentarium for NSCLC patients is not yet fully established, and the therapeutic impact of monotherapies (e.g., sunvozertinib, firmonertinib) versus combinations with standard platinum-based chemotherapy (e.g., zipalertinib, amivantamab) currently still lacks robust evidence to further change the therapeutic landscape for these patients. Therefore, results from the ongoing trials are eagerly awaited and are expected to shed some light on these open questions.
Review • Journal
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR L858R • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I
|
Ivesa (firmonertinib) • Zegfrovy (sunvozertinib) • zipalertinib (CLN-081)
1m
TROPION Lung15: A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov)
P3, N=744, Recruiting, AstraZeneca | Active, not recruiting --> Recruiting
Enrollment open
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I
|
cisplatin • Tagrisso (osimertinib) • carboplatin • pemetrexed • Datroway (datopotamab deruxtecan-dlnk) • simmitinib (SYHA1817)
Share via
